EVO756

June 29, 2026: Evommune, Inc. (NYSE: EVMN) reported top-line results from a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b trial of EVO756 (oral MRGPRX2 antagonist) in adults with moderate-to-severe chronic spontaneous urticaria (CSU). The 160-patient study (U.S., Europe, Canada, Japan) enrolled antihistamine-refractory CSU patients and tested three active dose regimens versus placebo. The trial did not meet the primary endpoint (mean change in Urticaria Activity Score over seven days [UAS7] at 12 weeks) at any dose, and the company said the Week 12 efficacy results do not support further development of EVO756 for CSU; doses were described as safe and well tolerated.

Evommune said it will continue developing EVO756 in other indications and remains on track to report top-line Phase 2b data in atopic dermatitis in Q3 2026. The company has initiated screening for a Phase 2b migraine prophylaxis trial of EVO756 and expects patient dosing to begin imminently.

Separately, Evommune noted it recently reported positive Phase 2a proof-of-concept data for EVO301 (IL-18BP fusion protein) in atopic dermatitis and plans to advance it into a Phase 2b AD trial.